Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.
Schettini F, Sirico M, Loddo M, Williams GH, Hardisty KM, Scorer P, Thatcher R, Rivera P, Milani M, Strina C, Ferrero G, Ungari M, Bottin C, Zanconati F, de Manzini N, Aguggini S, Tancredi R, Fiorio E, Fioravanti A, Scaltriti M, Generali D. Schettini F, et al. Among authors: aguggini s. Oncologist. 2024 Aug 23:oyae206. doi: 10.1093/oncolo/oyae206. Online ahead of print. Oncologist. 2024. PMID: 39177668 Free article.
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D. Schettini F, et al. Among authors: aguggini s. Front Oncol. 2021 Jun 28;11:686776. doi: 10.3389/fonc.2021.686776. eCollection 2021. Front Oncol. 2021. PMID: 34262869 Free PMC article.
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
Schettini F, De Bonis MV, Strina C, Milani M, Ziglioli N, Aguggini S, Ciliberto I, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Ferrero G, Ungari M, Locci M, Paris I, Scambia G, Ruocco G, Generali D. Schettini F, et al. Among authors: aguggini s. Sci Rep. 2023 Jul 24;13(1):11951. doi: 10.1038/s41598-023-38760-z. Sci Rep. 2023. PMID: 37488154 Free PMC article. Clinical Trial.
Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study.
Schettini F, Saracchini S, Bassini A, Marus W, Corsetti S, Specogna I, Bertola M, Micheli E, Wirtz RM, Laible M, Şahin U, Strina C, Milani M, Aguggini S, Tancredi R, Fiorio E, Sulfaro S, Generali D. Schettini F, et al. Among authors: aguggini s. Breast. 2024 Aug;76:103753. doi: 10.1016/j.breast.2024.103753. Epub 2024 May 25. Breast. 2024. PMID: 38815444 Free PMC article.
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment.
Ianza A, Giudici F, Pinello C, Corona SP, Strina C, Bernocchi O, Bortul M, Milani M, Sirico M, Allevi G, Aguggini S, Cocconi A, Azzini C, Dester M, Cervoni V, Bottini A, Cappelletti M, Generali D. Ianza A, et al. Among authors: aguggini s. Tumour Biol. 2020 Jun;42(6):1010428320925301. doi: 10.1177/1010428320925301. Tumour Biol. 2020. PMID: 32489146 Free article. Clinical Trial.
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer.
Andreis D, Bonardi S, Allevi G, Aguggini S, Gussago F, Milani M, Strina C, Spada D, Ferrero G, Ungari M, Rocca A, Nanni O, Roviello G, Berruti A, Harris AL, Fox SB, Roviello F, Polom K, Bottini A, Generali D. Andreis D, et al. Among authors: aguggini s. Breast. 2016 Oct;29:55-61. doi: 10.1016/j.breast.2016.07.003. Epub 2016 Jul 16. Breast. 2016. PMID: 27428471
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D. Roviello G, et al. Among authors: aguggini s. Future Oncol. 2016 Oct;12(19):2189-93. doi: 10.2217/fon-2016-0116. Epub 2016 Jun 21. Future Oncol. 2016. PMID: 27324108 Clinical Trial.
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, Bottini A, Harris AL, Fox SB. Generali D, et al. Among authors: aguggini s. J Natl Cancer Inst Monogr. 2015 May;2015(51):64-6. doi: 10.1093/jncimonographs/lgv018. J Natl Cancer Inst Monogr. 2015. PMID: 26063890 Clinical Trial.
36 results